Vitamin D for COVID-19 Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

2,024

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
COVID-19
Interventions
DIETARY_SUPPLEMENT

vitamin D

Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28

DIETARY_SUPPLEMENT

Placebo

Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28

Trial Locations (1)

02215

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Harvard Medical School (HMS and HSDM)

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

Fenway Health and Beth Israel Deaconess Medical Center

UNKNOWN

collaborator

Tishcon Corporation

UNKNOWN

collaborator

Takeda

INDUSTRY

collaborator

Quest Diagnostics-Nichols Insitute

INDUSTRY

collaborator

Laboratory Corporation of America

INDUSTRY

collaborator

Trialfacts

UNKNOWN

collaborator

Karolinska Institutet

OTHER

collaborator

Philanthropic donations

UNKNOWN

lead

Brigham and Women's Hospital

OTHER